BOTHELL, Wash., July 31, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the "Company"), today announced that the Company's second quarter 2019 financial results will be released after market close on Thursday, August 8, 2019, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business update.
To access the webcast, log on to the Investor Relations page of the BioLife Solutions website at www.biolifesolutions.com/earnings. Alternatively, you may access the live conference call by dialing (844) 825-0512 (U.S. & Canada) or (315) 625-6880 (International) with the following Conference ID: 1368786. A webcast replay will be available approximately two hours after the call and will be archived on www.biolifesolutions.com for 90 days.
About BioLife Solutions
BioLife Solutions is a leading supplier of cell and gene therapy tools. Its proprietary CryoStor® freeze media and HypoThermosol® shipping and storage media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Its recently acquired ThawSTAR® family of automated cell thawing devices reduce therapeutic and economic risk for cell and gene therapy developers by reducing the potential of administering a non-viable dose. For more information, please visit www.biolifesolutions.com, and follow BioLife on Twitter.
Media & Investor Relations
Roderick de Greef
Chief Financial Officer
(425) 402-1400
rdegreef@biolifesolutions.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/biolife-solutions-to-report-second-quarter-2019-financial-results-and-provide-business-update-on-august-8-2019-300893639.html
SOURCE BioLife Solutions, Inc.
